WO1999013885A1 - Modulation de reactions immunitaires - Google Patents

Modulation de reactions immunitaires Download PDF

Info

Publication number
WO1999013885A1
WO1999013885A1 PCT/US1998/019126 US9819126W WO9913885A1 WO 1999013885 A1 WO1999013885 A1 WO 1999013885A1 US 9819126 W US9819126 W US 9819126W WO 9913885 A1 WO9913885 A1 WO 9913885A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
immune
animal
alkyl
alkenyl groups
Prior art date
Application number
PCT/US1998/019126
Other languages
English (en)
Inventor
Carl John Landauer
Gabriel Johannes Du Preez
Volker Reinhard Schillack
Derrick Cecil Attfield
Johannes Beyers Van Den Bogaerde
Original Assignee
Frangold Holdings Limited
Davis, Joanne, T.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frangold Holdings Limited, Davis, Joanne, T. filed Critical Frangold Holdings Limited
Priority to EP98946998A priority Critical patent/EP1019063A4/fr
Priority to CA002304119A priority patent/CA2304119A1/fr
Priority to BR9812321-1A priority patent/BR9812321A/pt
Priority to NZ503418A priority patent/NZ503418A/xx
Priority to JP2000511505A priority patent/JP2001516721A/ja
Priority to AU93890/98A priority patent/AU737867B2/en
Priority to IL13509198A priority patent/IL135091A0/xx
Publication of WO1999013885A1 publication Critical patent/WO1999013885A1/fr
Priority to NO20001341A priority patent/NO20001341L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • THIS invention relates to the treatment of conditions in the human body which are associated with inappropriate immune responses. More
  • this invention is concerned with the treatment of conditions in which the inappropriate immune response is associated with inappropriate-
  • Tyrosine Kinase hereinafter referred to as "PTK”
  • CDK Cycline Dependent Kinase
  • the invention consequently provides for the treatment of and for medicaments for use in the treatment of, a large variety of ailments
  • T lymphocytes also known as T-cells
  • B-cells the T lymphocytes
  • infection of the animal body or to endogenous immune stimulants, for example oncogenic transformation, is to cause the activation of the
  • immunological mediators including cytokines, lymphokines, chemokines, growth factors and cytotoxic cells and usually also gives rise to the
  • the response of the immune system is sometimes abnormal and
  • Such abnormality in immune cell activity may simply be
  • the present invention is directed at the treatment of such conditions as will appear below.
  • cytotoxic cells including the presence of cytotoxic cells, and/or of an
  • the immune response may persist even after the causative agent or stimulant, such as, for example, a viral or microbial
  • Immune cells and in particular T
  • lymphocytes are dependent for their biological function on signal transduction through the T cell receptor which is unique to, and present
  • the T cell receptor is a complex group of
  • CD 4 CD 8
  • Tyrosine Kinases phosphorilate certain proteins leading to the development
  • Tyrosine Kinase [PTK] plays an important role. This enzyme is a protein
  • Such toxicity as DMF has at high levels of concentration in the human body is attributed to its depletion of
  • R 2 and R 3 are the same or different and each is selected from the
  • n is any number from 2 to 5, or the group -(CH 2 ) 2 -0-(CH 2 ) 2 and metabolites and prodrugs thereof.
  • the immune response to be affected by the above method may be an immune response of the immune cells forming part of the immune system of the body.
  • the immune cells may be T lymphocytes and or B lymphocytes.
  • the method may be performed to reduce the expression or secretion of immune cell products in the body.
  • R j is selected from the group consisting of H and lower [i.e. to C 3 ]
  • n is any number from 2 to 5, or the group -(CH 2 ) 2 -0-(CH 2 ) 2 and metabolites and prodrugs thereof.
  • R is selected from the group consisting of H and lower [i.e. C, to C 3 ] alkyl and C 2 to C 3 alkenyl groups;
  • R 2 and R 3 are the same or different and each is selected from the group consisting of H, lower [i.e. C, to C 3 ] alkyl and C 2 to C 3 alkenyl
  • n is any number from 2 to 5, or the group -(CH 2 ) 2 -0-(CH 2 ) 2
  • composition comprising a compound selected from the group consisting of compounds of the general chemical formula (I)
  • R is selected from the group consisting of H and lower [i.e. C, to C 3 ] alkyl and C 2 to C 3 alkenyl groups;
  • R 2 and R 3 are the same or different and each is selected from the group consisting of H, lower [i.e. to C 3 ] alkyl and C 2 to C 3 alkenyl
  • n is any number from 2 to 5, or the group -(CH 2 ) 2 -0-(CH 2 ) 2
  • treated may be any one of the following:
  • SIRS Systemic Inflammatory Response Syndrome
  • the compounds of choice is dimethylformamide and its metabolites namely N-methylformamide, N-
  • the medicament according to the invention is adapted in use to administer to the patient a quantity of
  • the compound may be administered by
  • any route of administration such as orally, nasally, rectally, intravenously,
  • administration of the compound is transdermally. Preferably, however, it
  • transdermal patch is administered by a transdermal patch.
  • mixed lymphocytes were exposed to a non-specific stimulator of lymphocytes, such as PHA at 1 to 10 ⁇ g per
  • metabolic activity is not the result of direct cell toxicity as is evidenced by
  • T lymphocytes to certain T lymphocyte specific antigens and antigen,
  • transdermal administration system that is able to deliver a variety of drugs including DMF and the above-mentioned related compounds
  • the patch design parameters considered important include the following:
  • the patch must have pre-determined dimensions as it determines the amount of active ingredient [drug] absorbed over a certain time.
  • Drug concentration should be variable according to patient profile.
  • the patch must be stable, and deliver repeatable therapeutic
  • the patch and the drug must have a relative long shelf life.
  • Membrane pore size of 0.05-0.45 micron depending on which drug is administered.
  • Anti-irritation agent - Vitamin E (This agent can be applied before,
  • Indirect administration of the drug such as DMF may be done by
  • Therapeutic agent dosage can be predetermined according to patient's
  • Patch is very stable, has an unlimited shelf life, and agent administered from an ampoule has at least a two year expiry date,
  • Peripheral human lymphocytes were isolated from whole blood of healthy
  • peripheral whole blood is diluted 1:2 with phosphate buffered saline or cell culture media such as RPMI1640.
  • a density gradient such as
  • Histopaque 1077 [Sigma Cat # 1077] is then layered underneath the diluted peripheral blood, taking care to create a sharp interface. The density
  • This layer is then removed and further processed by placing the buffy coat in an additional tube and washing the cells washed 3 times
  • the cells are centrifuged at 400 g for 9 minutes. After the third wash the lymphocytes
  • the cells are collected from the pellet.
  • the cells are counted and diluted to the desired cell concentration.
  • DMF concentrations were prepared using complete cell culture
  • the isolated lymphocytes were diluted to the required concentration using
  • the prepared lymphocytes were placed in 96 well cell culture plates at a
  • PHA Phyto-Heame-Agglutinin
  • lymphocytes This demonstrates a significant inhibition of metabolic activity in the culture well which correlates very closely with the level of
  • AlamarBlue is observed for lymphocytes exposed to 0.05% DMF
  • lymphocytes were isolated the lymphocytes were exposed to DMF at various
  • the Tyrosine kinase activity was: 5, 15, 30, 75, 120 and 180 minutes.
  • the Tyrosine kinase activity was: 5, 15, 30, 75, 120 and 180 minutes.
  • tested lymphocytes might be the result of stimulation of certain tyrosine
  • the presented graphs are typical examples of many graphs obtained.
  • HELA a Cervix cancer cell line
  • HEP3B a liver cancer cell
  • the inhibitor was used in 10% DMSO solution. The test was carried under the following conditions and yielded the results

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un procédé permettant d'influencer ou de moduler chez un animal une stimulation ou une suppression du produit de cellules immunitaires, suite à une réaction immunitaire à un stimulant immunitaire externe ou endogène. Le procédé comporte les étapes consistant à administrer à cet animal une quantité efficace du point de vue d'une modulation immunitaire, et non toxique, d'un composé sélectionné dans le groupe constitué par des composés représentés par la formule (I) chimique générale: R1-CO-NR2R3 (I), dans laquelle R1 est sélectionné dans le groupe constitué par H, un groupe alkyle inférieur (c.-à-d. C1 à C3) et un groupe alcényle C2 à C3; R2 et R3 sont les mêmes ou différents, et chacun est sélectionné dans le groupe constitué par H, un groupe alkyle inférieur (c.-à-d. C1 à C3) et un groupe alcényle C2 à C3 qui peuvent être éventuellement halogénés ou hydroxylés, ou lorsqu'ils sont combinés l'un avec l'autre, peuvent former un groupe -(CH2)n dans lequel n est un nombre compris entre 2 et 5, ou le groupe -(CH2)2-O-(CH2)2, des métabolites ou des promédicaments de ceux-ci. Le procédé est utile pour traiter diverses affections associées à des réactions immunitaires inappropriées. L'invention concerne l'utilisation de composés représentés par la formule (I) pour fabriquer des médicaments utiles pour le traitement de telles affections, et des préparations pharmaceutiques renfermant ceux-ci.
PCT/US1998/019126 1997-09-16 1998-09-16 Modulation de reactions immunitaires WO1999013885A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP98946998A EP1019063A4 (fr) 1997-09-16 1998-09-16 Modulation de reactions immunitaires
CA002304119A CA2304119A1 (fr) 1997-09-16 1998-09-16 Modulation de reactions immunitaires
BR9812321-1A BR9812321A (pt) 1997-09-16 1998-09-16 Modulação de respostas imunológicas
NZ503418A NZ503418A (en) 1997-09-16 1998-09-16 Use of dimethylformamide in the modulation of immune responses
JP2000511505A JP2001516721A (ja) 1997-09-16 1998-09-16 免疫応答の調節
AU93890/98A AU737867B2 (en) 1997-09-16 1998-09-16 Modulation of immune responses
IL13509198A IL135091A0 (en) 1997-09-16 1998-09-16 Modulation of immune responses
NO20001341A NO20001341L (no) 1997-09-16 2000-03-15 Modulering av immunresponser

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA978319 1997-09-16
ZA97/8319 1997-09-16

Publications (1)

Publication Number Publication Date
WO1999013885A1 true WO1999013885A1 (fr) 1999-03-25

Family

ID=25586589

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/019126 WO1999013885A1 (fr) 1997-09-16 1998-09-16 Modulation de reactions immunitaires

Country Status (10)

Country Link
EP (1) EP1019063A4 (fr)
JP (1) JP2001516721A (fr)
CN (1) CN1279612A (fr)
AU (1) AU737867B2 (fr)
BR (1) BR9812321A (fr)
CA (1) CA2304119A1 (fr)
IL (1) IL135091A0 (fr)
NO (1) NO20001341L (fr)
NZ (1) NZ503418A (fr)
WO (1) WO1999013885A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1201237A1 (fr) * 2000-10-26 2002-05-02 Virodene Pharmaceutical Holdings (PTY) Ltd. Composition comprenant une amide ou un dérivé dialkylsulphoxide destiné au traitement du cancer
WO2005053641A1 (fr) * 2003-12-05 2005-06-16 Namibia Medical Investments (Pty) Limited Timbre

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814659A (en) * 1996-04-23 1998-09-29 Dtr Dermal Therapy (Barbados) Inc. Topical analgesic composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts Service (C A S); 1 January 1900 (1900-01-01), XP002915216, Database accession no. 73-120262 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1201237A1 (fr) * 2000-10-26 2002-05-02 Virodene Pharmaceutical Holdings (PTY) Ltd. Composition comprenant une amide ou un dérivé dialkylsulphoxide destiné au traitement du cancer
WO2005053641A1 (fr) * 2003-12-05 2005-06-16 Namibia Medical Investments (Pty) Limited Timbre

Also Published As

Publication number Publication date
CA2304119A1 (fr) 1999-03-25
IL135091A0 (en) 2001-05-20
NO20001341L (no) 2000-05-16
JP2001516721A (ja) 2001-10-02
AU9389098A (en) 1999-04-05
NZ503418A (en) 2001-02-23
EP1019063A4 (fr) 2003-09-03
NO20001341D0 (no) 2000-03-15
CN1279612A (zh) 2001-01-10
EP1019063A1 (fr) 2000-07-19
AU737867B2 (en) 2001-09-06
BR9812321A (pt) 2000-09-05

Similar Documents

Publication Publication Date Title
Kaufman Clinical cure of herpes simplex keratitis by 5-iodo-2'-deoxyuridine
Monteiro et al. Brain interference: revisiting the role of IFNγ in the central nervous system
Wang et al. The role of glycogen synthase kinase 3 in regulating IFN-β–mediated IL-10 production
CN114026067A (zh) 用于治疗冠状病毒和小核糖核酸病毒感染的肽模拟物
RU2770754C1 (ru) Комбинация ингибитора гистондеацетилазы и ингибитора протеинкиназы и ее фармацевтическое применение
Del Pozo et al. Murine eosinophils and IL-1: alpha IL-1 mRNA detection by in situ hybridization. Production and release of IL-1 from peritoneal eosinophils.
Wu et al. Recombinant osteopontin attenuates brain injury after intracerebral hemorrhage in mice
Qin et al. Effects of naringin on learning and memory dysfunction induced by gp120 in rats
Richard et al. Elucidating the pivotal immunomodulatory and anti‐inflammatory potentials of chloroquine and Hydroxychloroquine
Simeon et al. d-Cycloserine therapy of psychosis by symptom provocation
Blaževski et al. Betulinic acid regulates generation of neuroinflammatory mediators responsible for tissue destruction in multiple sclerosis in vitro
Fukuda et al. Adenine inhibits TNF-α signaling in intestinal epithelial cells and reduces mucosal inflammation in a dextran sodium sulfate-induced colitis mouse model
Olianas et al. Inhibition of TNF-α-induced neuronal apoptosis by antidepressants acting through the lysophosphatidic acid receptor LPA1
Liu et al. Pro-angiogenic effect of IFNγ is dependent on the PI3K/mTOR/translational pathway in human retinal pigmented epithelial cells
Constantin et al. Sulfatides trigger cytokine gene expression and secretion in human monocytes
Ren et al. Staphylococcus aureus Protein A induces osteoclastogenesis via the NF‑κB signaling pathway
AU737867B2 (en) Modulation of immune responses
IP et al. Effect of non-steroidal anti-inflammatory drugs on neutrophil chemotaxis—an in vitro and in vivo study
CN105311636B (zh) 一种抗疱疹病毒软膏剂及其制备方法
Inada et al. Antisense hippocampal knockdown of NMDA-NR1 by HVJ-liposome vector induces deficit of prepulse inhibition but not of spatial memory
CN101701218B (zh) 一种抑制Th1和Th17分化的免疫调节性寡聚脱氧核苷酸及应用
JPH0544930B2 (fr)
Chihara et al. Priming effect of RANTES on eosinophil oxidative metabolism
ES2281195T3 (es) Factores inmunomoduladores para el tratamiento inmunosupresor y antialergico.
US11944601B2 (en) Applications of ellagic acid in preparation of immunomodulatory medicines for treatment of neuromyelitis optica or immune rejection after skin transplantation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 135091

Country of ref document: IL

Ref document number: 98810397.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2304119

Country of ref document: CA

Ref document number: 2304119

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 93890/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 503418

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2000 511505

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1998946998

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09508642

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1998946998

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 93890/98

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1998946998

Country of ref document: EP